Stock 300204 STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Staidson (Beijing) BioPharmaceuticals Co., Ltd. Share Price

Equities

300204

CNE100001237

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
6.3 CNY -2.17% Intraday chart for Staidson (Beijing) BioPharmaceuticals Co., Ltd. +11.50% -37.99%
04-24 Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-25 Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2022 549M 75.77M 6.07B Sales 2023 364M 50.26M 4.02B Capitalization 4.85B 670M 53.65B
Net income 2022 -197M -27.19M -2.18B Net income 2023 -399M -55.07M -4.41B EV / Sales 2022 11.2 x
Net cash position 2022 259M 35.76M 2.86B Net cash position 2023 44.23M 6.1M 489M EV / Sales 2023 13.2 x
P/E ratio 2022
-33.2 x
P/E ratio 2023
-12.1 x
Employees 555
Yield 2022 *
-
Yield 2023
-
Free-Float 25.45%
More Fundamentals * Assessed data

Chart Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Dynamic Chart

Latest news about Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Staidson BioPharmaceuticals Co., Ltd.(XSEC:300204) added to S&P Global BMI Index CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Staidson BioPharmaceuticals Co., Ltd. amended terms of the transaction CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Staidson Pharma Unit Gets FDA's Emergency Use Authorization for COVID-19 Drug; Shares Soar 18% MT
Review Into Staidson Biopharma Unit's Anti-COVID-19 Drug Shows Safety, Tolerability in Patients; Shares Jump 5% MT
Staidson's Respiratory Drug Shows Safety in Trial MT
Chinese Shares Finish Lower; Staidson Falls 8% After Signing R&D Deal With Germany’s InflaRx MT
Staidson Forms R&D Deal With Germany’s InflaRx MT
Staidson BioPharmaceuticals Co., Ltd. announced that it expects to receive CNY 580 million in funding CI
Inflarx Gmbh and Staidson Biopharmaceuticals Co., Ltd Enters into Third Addendum to the Co-Development Agreement CI
InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson BioPharmaceuticals Co., Ltd. CI
More news

Press releases Staidson (Beijing) BioPharmaceuticals Co., Ltd.

InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19 AQ
More press releases

Quotes and Performance

1 day-2.17%
1 week+11.50%
Current month-6.80%
1 month-7.62%
3 months-27.84%
6 months-31.89%
Current year-37.99%
More quotes

Highs and lows

1 week
5.51
Extreme 5.51
7.10
1 month
5.44
Extreme 5.44
7.10
Current year
5.44
Extreme 5.44
10.38
1 year
5.44
Extreme 5.44
13.33
3 years
5.44
Extreme 5.44
29.85
5 years
5.44
Extreme 5.44
29.85
10 years
5.44
Extreme 5.44
45.37
More quotes

Managers and Directors - Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Managers TitleAgeSince
Chao Wang CEO
 Chief Executive Officer 42 30/06/11
Shi Cheng Li DFI
 Director of Finance/CFO 42 25/08/20
Zhi Wen Zhou PSD
 President 59 31/12/01
Members of the board TitleAgeSince
Hong Shan Zhang CHM
 Chairman 60 31/12/01
Zhi Wen Zhou CHM
 Chairman 59 31/12/01
Tao Li BRD
 Director/Board Member 61 31/12/07
More insiders

ETFs positioned on Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.14% -
More ETFs positioned on Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Quotes

Date Price Change Volume
26/04/24 6.3 -2.17% 13,344,480
25/04/24 6.44 +8.60% 20,493,430
24/04/24 5.93 +0.68% 3,745,100
23/04/24 5.89 +2.43% 5,902,655
22/04/24 5.75 +1.77% 4,771,600

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes

Company Profile

Staidson (Beijing) Biopharmaceuticals Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of innovative therapeutic medicine with independent intellectual property rights including protein medicine, genetic medicine and chemical medicine, among others. The Company’s products include mouse nerve growth factor for injection, which are applied in the neuroprotection and treatment of nerve injuries, as well as polyethylene glycol electrolyte powders, which are applied in the bowel cleansing and treatment of constipation. The Company mainly distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
26/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

1st Jan change Capi.
STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. Stock Staidson (Beijing) BioPharmaceuticals Co., Ltd.
-37.99% 415M
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 300204 Stock